Triptans and NSAIDs remain the primary choices to reduce pain and improve function in the acute treatment of episodic migraine in patients who do not have contraindications. A systematic review and meta-analysis of data from more than 28,000 participants across 115 trials and 15 systematic reviews showed high and moderate strength evidence for the two ...
Triptans and NSAIDs remain first choice for migraine: review
By Mardi Chapman
21 Jun 2021